Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

FDA issues new draft guidance on decentralised clinical trials

The document includes recommendations on trial design and the use of digital health technologies

- PMLiVE

Confidently omnichannel: the critical role of customer engagement

Why a successful leap from multichannel to omnichannel is within your grasp

AMICULUM® collaborates with the University of Dundee to develop a new Master’s course in Science and Health Communication

AMICULUM Limited is proud to announce its collaboration with the University of Dundee in developing a Master’s course in Science and Health Communication. The Master’s course was an idea conceived...

Amiculum

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Supply chain challenges in 2023

Looking at the supply chain challenges pharmaceutical companies could face

The Path to Patient Centricity

How do we move towards a more patient-centric way of working?

Mednet

- PMLiVE

Astellas to acquire Iveric Bio for approximately $5.9bn

The deal includes the US drugmaker’s lead candidate for geographic atrophy

- PMLiVE

Pfizer’s next-generation pneumococcal vaccine granted FDA approval

The vaccine can help protect against 20 serotypes of the streptococcus pneumoniae bacteria

- PMLiVE

Maintaining the long-term health of the agency sector

How pharma and agency can work together to ensure our ecosystem remains in great health

- PMLiVE

GSK’s RSV vaccine candidate recommended by CHMP for older adults

RSV infections in older adults account for over 270,000 hospitalisations each year in Europe

- PMLiVE

Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The two treatments could benefit up to 600 patients each year in England

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links